
Kevin John Whitehead MD
Adult Congenital Heart Disease, Echocardiography
Associate Professor, Internal Medicine, University of Utah School of Medicine
Join to View Full Profile
50 N Medical DrSalt Lake City, UT 84132
Phone+1 801-585-7676
Dr. Whitehead is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Utah HealthFellowship, Cardiovascular Disease, 1998 - 2004
University of Western OntarioInternship/Residency, 1995 - 1998
University of AlbertaClass of 1995
Certifications & Licensure
UT State Medical License 1998 - 2028
CO State Medical License 2024 - 2027
ID State Medical License 2014 - 2027
MT State Medical License 2021 - 2027
NM State Medical License 2024 - 2027
NV State Medical License 2007 - 2027
WY State Medical License 2010 - 2027
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Cardiovascular Disease
American Board of Internal Medicine Adult Congenital Heart Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite (with Beaker), Epic Systems Corporation, 2013-2017
Clinical Trials
- Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia Start of enrollment: 2010 Apr 08
- North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Start of enrollment: 2011 Aug 01
Publications & Presentations
PubMed
- Characteristics associated with clinical response to pomalidomide in hereditary hemorrhagic telangiectasia.Hanny Al-Samkari, Sonia M Thomas, Derek Marsh, Raj S Kasthuri, Vivek N Iyer
Blood Advances. 2026-05-12 - 3 citationsPomalidomide for hereditary hemorrhagic telangiectasia: after trial longitudinal assessment study (PATH-HHT ATLAS).Ellen Zhang, Raj S Kasthuri, Joseph Parambil, Vikas Prasad, Vivek N Iyer
Blood Advances. 2026-03-10 - 1 citationsValidation and clinical application of the hereditary hemorrhagic telangiectasia-specific quality of life scale.Hanny Al-Samkari, Raj S Kasthuri, Vivek N Iyer, Allyson M Pishko, Jake E Decker
Journal of Thrombosis and Haemostasis. 2026-01-01
Journal Articles
- Atorvastatin Treatment of Cavernous Angiomas with Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) TrialAmy L Akers, Kevin J Whitehead, Gregory A Christoforidis, Daniel F Hanley, Kelly D Flemming, Sean P Polster, James K Liao, Matthew Sorrentino, Cornelia Lee, Issam A Aw..., Neurosurgery
Press Mentions
Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients with Hereditary Hemorrhagic TelangiectasiaAugust 20th, 2018
Simple Saline Spray Could Be as Effective as Drug Therapy for Treating Chronic NosebleedsSeptember 6th, 2016
Grant Support
- KRIT1 In Vascular Development And DysfunctionNational Institute Of Neurological Disorders And Stroke2011
- The Cellular Basis Of CCM Gene Function In DevelopmentNational Heart, Lung, And Blood Institute2006–2010
Professional Memberships
- Fellow
- Member
- North American Vascular Biology Organization - NAVBOMember
External Links
- Profile Pagehttp://healthcare.utah.edu/fad/mddetail.php?physicianID=u0114851
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









